Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...

Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...

In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...

It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

FDA selected seven participants from 80+ requests using a scoring rubric emphasizing supply need, facility development stage, time-to-market, and manufacturing innovation. Amneal will make sterile ...